Latest Competition News

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Jcurve Solutions Limited reported a significant turnaround in FY25 with a Normalised EBITDA profit and a narrowed net loss, despite an 11% revenue decline. The company also strengthened its Asia presence through acquisition and boosted liquidity with a $1 million capital raise.

Beonic Ltd reported a significantly reduced net loss of $3.17 million for FY2025, alongside improved margins and EBITDA profitability, underpinned by a major North African airport contract and a $4.18 million convertible note raise to accelerate growth.

Magontec Limited posted a 29% decline in revenue to $29.47 million for the first half of 2025, alongside a net loss of $3.96 million, while shutting down its Qinghai subsidiary. The results highlight ongoing challenges in the steel manufacturing sector.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Codeifai Limited reported a near doubling of its half-year loss to $3.93 million, alongside a 32% revenue drop, while pursuing transformative AI and quantum security acquisitions and securing $2.35 million in fresh capital.

Wide Open Agriculture Limited has trimmed its annual loss to $7.09 million while expanding its lupin protein sales pipeline across key international markets and optimizing production in Germany.

Atomos Ltd reported a 9% revenue decline to $32.7 million for FY25 but improved its loss after tax by 35%, driven by cost restructuring and tighter expense control amid challenging market conditions.

OMG Group Limited reported a 63% revenue surge to $4.13 million in FY2025, driven by its acquisition of Good Oats Pty Ltd and strong growth in its Blue Dinosaur brand. The company also trimmed its loss by 18% and improved gross margins, signaling operational progress despite ongoing challenges.

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.

Seafarms Group Limited reported a reduced loss of $11.7 million for FY2025, despite a 43% drop in revenue and ongoing legal challenges surrounding Project Sea Dragon. Production setbacks from flooding and subdued market demand weighed heavily on results.

EVE Health Group has reported a 19% decline in revenue and a 17% increase in net loss for the financial year ended June 2025, highlighting ongoing challenges in its health and wellness segments.